



HAL
open science

Psychosocial problems in women attending French, German and Spanish genetics clinics before and after targeted or multigene testing results: an observational prospective study

Anne Brédart, Jean-Luc Kop, Julia Dick, Alejandra Cano, Antoine de Pauw, Amélie Anota, Joan Brunet, Peter Devilee, Dominique Stoppa-Lyonnet, Rita K. Schmutzler, et al.

► To cite this version:

Anne Brédart, Jean-Luc Kop, Julia Dick, Alejandra Cano, Antoine de Pauw, et al.. Psychosocial problems in women attending French, German and Spanish genetics clinics before and after targeted or multigene testing results: an observational prospective study. *BMJ Open*, In press. hal-02275440v1

HAL Id: hal-02275440

<https://hal.univ-lorraine.fr/hal-02275440v1>

Submitted on 30 Aug 2019 (v1), last revised 24 Sep 2019 (v2)

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Psychosocial problems in women attending French, German and Spanish genetics clinics before and after targeted or multigene testing results: an observational prospective study.

Short title: Psychosocial problems in HBOC testing

Anne Brédart 1,2, Jean-Luc Kop 3, Julia Dick 4, Alejandra Cano 5, Antoine De Pauw 6, Amélie Anota 7,8, Joan Brunet 9, Peter Devilee 10, Dominique Stoppa-Lyonnet 6, Rita Schmutzler 4, Sylvie Dolbeault 1,11

1 Institut Curie, Supportive Care Department, Psycho-oncology Unit, Paris;

2 University Paris Descartes, Boulogne-Billancourt, France;

3 Université de Lorraine, 2LPN (CEMA), Nancy, France;

4 Familial Breast and Ovarian Cancer Centre, Cologne University Hospital and Faculty of Medicine, Cologne, Germany;

5 University Autónoma of Barcelona, Clinical and Health Psychology Department, Barcelona, Spain;

6 Institut Curie, Cancer genetic clinic, Paris, France;

7 Methodology and Quality of Life in Oncology unit (INSERM UMR 1098), University Hospital of Besançon, France;

8 French National Platform Quality of Life and Cancer, Besançon, France;

9 Catalan Institute of Oncology, Barcelona, Spain;

10 Leiden University Medical Center, Department of Human Genetics / Department of Pathology, Leiden, Netherlands;

11 CESP, University Paris-Sud, UVSQ, INSERM, University Paris-Saclay, Villejuif, France.

Address for correspondence: Anne Brédart, PhD, Institut Curie, Psycho-Oncology Unit, 26 rue d'Ulm,

75.005 Paris Cedex 05, France. Telephone: +33-1-44 32 40 33, E -mail: anne.bredart@curie.fr

Keywords: Multigene, targeted testing, hereditary breast and ovarian cancer, psychosocial problems, cross-cultural, service delivery.

Abstract

Objectives and setting: Advances in multigene panel testing for cancer susceptibility has increased the complexity of counselling, requiring particular attention to counselees' psychosocial needs. Changes in psychosocial problems before and after genetic testing were prospectively compared between genetic test results in women tested for breast or ovarian cancer genetic susceptibility in French, German, and Spanish clinics.

Participants and measures: Among 752 counselees consecutively approached, 646 (86%) were assessed after the initial genetic consultation (T1), including 510 (68%) affected with breast cancer, of which 460 (61%) were assessed again after receiving the test result (T2), using questionnaires addressing genetic-specific psychosocial problems (PAHC-six scales). Socio-demographic and clinical data were also collected.

Results: Seventy-nine (17.2%), 19 (4.1%), 259 (56.3%), 44 (9.6%), 59 (12.8%) women received a BRCA1/2, another high/moderate-risk pathogenic variant (PV), negative uninformative (NU), true negative (TN), or variant of uncertain significance result (VUS), respectively. On multiple regression analyses, compared to women receiving another result, those with a VUS decreased more in psychosocial problems related to hereditary predisposition (e.g., coping with the test result) ($\beta = -0.11$, $p < 0.05$) and familial/social issues (e.g. risk communication) ($\beta = -0.13$, $p < 0.05$), almost independently from their problems before testing. Women with a PV presented no change in hereditary predisposition problems and, so as women with a TN result, a non-significant increase in familial/social issues. Other PAHC scales (i.e., Emotions, Familial Cancer, Personal Cancer, Children-Related Issues) were not affected by genetic testing.

Conclusions: In women tested for breast or ovarian cancer genetic risk in European genetics clinics, psychosocial problems were mostly unaffected by genetic testing. Apart from women receiving a VUS result, those with another test result presented unchanged needs in counselling in particular about hereditary predisposition and familial/social issues.

Strength and limitations of this study

The PAHC questionnaire proved useful for monitoring further counselling needs after multigene or targeted HBOC testing.

The study was performed in cancer genetics practices from three European countries.

The study findings are valid to women opting for genetic testing and test disclosure, and who were mainly affected with breast cancer and could not be compared with an appropriate control group.

Only one genetics clinic per country precludes comparisons of psychosocial difficulties between countries.

Further research should address the variability between clinicians in communication style.

Introduction

A hereditary predisposition explains approximately 10% of all breast cancers (BC)¹. With next-generation DNA sequencing and the discovery of new cancer susceptibility genes, the simultaneous analysis of multiple genes, so-called multigene panel testing, is implemented in clinical practice². In addition to the highly penetrant hereditary breast or ovarian cancer (HBOC) predisposition genes such as BRCA1, BRCA2 and PALB2, multigene panels also involve breast cancer (BC) (e.g., ATM, CHEK2)³, ovarian cancer (OC) (e.g., BRIP1, RAD51C or RAD51D)⁴ moderate-risk genes, and other hereditary syndrome high-penetrant BC susceptibility genes (e.g., TP53, PTEN, CDH1 or STK11). Multigene testing is generally primarily proposed to a woman in the family who developed BC or OC (index case). If a pathogenic variant is found, blood relatives are currently proposed for targeted genetic testing.

Individuals undergoing genetic testing for cancer risk ask help to appraise and manage their risk of developing cancer, inform their family about cancer genetic predisposition, clarify their children's risk, and when affected by cancer, gain information about why they developed the disease^{5 6}. They experience counselling needs for specific problems related to the hereditary predisposition, familial and personal cancer, familial and social relationships, and children-related issues within the cancer genetic context⁷, which may elicit request for psychological help⁸.

Different national guidelines in Europe recommend genetic counselling before and after genetic testing for breast or ovarian cancer risk⁹⁻¹². This healthcare discipline is defined as "the process of helping people understand and adapt to the medical, psychological, and familial implications of genetic contributions to disease"¹³, and so it aims at responding to counselees' specific psychosocial problems¹⁴.

Genetic counselling provides a large quantity of information involving genetic and statistic concepts, which may be ambiguous and imprecise^{15 16}. With multigene panel testing, this complexity is increased especially because of the addition of moderate-risk genes and the identification of an increased number of variants of uncertain significance (VUS)¹⁷. Both have unclear clinical recommendations^{16 18}. Prolonged clinical distress is uncommon after single-gene testing for HBOC susceptibility¹⁹. However, an inconclusive result such as a VUS may elicit misunderstanding^{20 21}, uncertainty^{21 22} and decisional conflicts about clinical management²³, potentially leading to increased distress²⁴, miscommunication between family members²⁵ and inadequate cancer risk management decisions^{21 26 27}. Upon receiving a pathogenic moderate-penetrance gene variant, counselees may experience higher distress and uncertainty compared to a negative, VUS and even a pathogenic high-penetrance variant²⁸.

Few studies have addressed psychosocial outcomes after multigene testing for cancer risk²⁸⁻³⁰. This observational prospective study assessed the effect of HBOC testing on specific psychosocial problems in women attending different European genetics clinics (i.e., in France, Germany and Spain). Specifically estimating the effect of genetic testing, we assessed changes in these problems before and after test disclosure. The outcome measure consists in a recently validated questionnaire purported to monitor a comprehensive range of psychosocial problem specifically relevant to the cancer genetics context³¹. Indeed, counselees may experience a wide range of psychosocial problems, which unaddressed may exacerbate their distress³² and so pointing to these problems according to the test result might target specific counselling needs³³. We hypothesized a lower decrease before and after testing in psychosocial problems of women receiving a high/moderate-risk pathogenic variant^{28 30 34 35} or VUS result^{21 36} compared to women receiving a negative test result. We also estimated the effect of psychosocial problems before testing on the relationship between the genetic result and psychosocial problems after testing to further clarify remaining counselling needs, as initial worries often predict subsequent difficulties^{6 19 28 30}.

Methods

Patient and Public Involvement

Counselees were involved in the study by providing feedback on the content, format and burden of the survey. Questionnaires were revised according to counselees' feedback. They will be involved in plans for dissemination of the study. The study results will be publicly available through the website of "Breast Cancer Risk after Diagnostic Gene Sequencing" (BRIDGES) research program (<https://bridges-research.eu>).

Study design and setting

An observational prospective study³⁷ was undertaken within the clinical translation work package of "Breast Cancer Risk after Diagnostic Gene Sequencing" (BRIDGES) research program (<https://bridges-research.eu>). The study design is showed in figure 1. Accrual took place from November 2016 to April 2018 in the genetics clinics of Institute Curie (France), University Hospital Cologne (Germany) or Barcelona Institute of Oncology (Spain).

Breast cancer gene testing and counselling

BC gene testing and counselling were specific by setting and based on specific guidelines in each country (Groupe Génétique et Cancer (GGC) in France^{12 38}; German Consortium for Hereditary Breast and Ovarian Cancer-German Gynaecological Oncology Group in Germany (GC-HBOC-AGO)¹⁰; "Oncoguia" guidelines in Spain¹¹).

Genetic counselling was considered important, before and after testing^{9 10 38}, and to be performed according to principles of patient-centred communication¹⁰.

Across guidelines, gene panel testing was mainly performed in women affected with BC (index cases). A 12-gene, 34-gene, and 9-gene panel was tested in France (Paris), Germany (Cologne) and Spain (Barcelona), respectively. Targeted testing was proposed to relatives of pathogenic variant carriers.

Genetic counselling was provided in face-to-face consultations: in the French setting, pre-test consultation was provided by one of five genetic counsellors with a biology background and the result disclosure by one of five medical geneticists; in the German setting, pre-test and post-test consultations were provided by one of ten physicians, including a medical geneticist and nine gynaecologists and in the Spanish setting, by one of four genetic counsellors with a background in biology for one of them or nursing for the three others.

The pre-test consultation lasted up to one hour. Women were informed about hereditary cancer risks and the genetic testing process. Information most systematically provided at that time comprised the probability that the woman be carrier of a pathogenic mutation and cancer risks (breast or ovarian) according to the test result.

The duration of the post-test consultation ranged from fifteen minutes in case of a negative result to one hour for a pathogenic variant. Information on cancer risks and medical management was validated in multidisciplinary team meetings. Women were systematically informed about their cancer risk in words and, depending on the test result and the country setting, also in percentage (i.e., systematically in women receiving a pathogenic variant in the German setting, most frequently in these women in the French and Spanish settings, never in percentage in case of negative

uninformative in the Spanish setting), using 'Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm' (BOADICEA) estimates 39 in the French and German settings.

Women receiving an uninformative test result were generally told that no pathogenic variant was found which does not preclude a possible yet unknown genetic predisposition explaining the family history of cancer. When a VUS was identified, women were told that this result does not allow for concluding that a causal variant was found; however, clinicians would keep the woman informed if this variant was reclassified as pathogenic in the future. Women receiving a true negative result were informed that their risk of breast or ovarian cancer was the same as the general population.

A psychological consultation was systematically proposed at the pre- and post-test consultations but only available on-site in the French and German settings. Further details on genetic counselling 40 in the three settings are provided in supplementary online material S1.

Study participants

Seven hundred and fifty-two women aged above 18, eligible for BC risk testing according to national criteria, unaffected or affected with a non-metastatic BC were consecutively approached, including 258, 324 and 170 in the French, German and Spanish genetics clinics, respectively. Women with a BC recurrence, a personal history of ovarian cancer or a major psychiatric disorder were not included.

In each setting, women accepting to participate in the study received a set of questionnaires to fill in at home and returned the first questionnaire within one month after the initial (pre-test) consultation (T1) and then two months after the genetic test result disclosure (post-test) consultation (T2).

Study variables and sources of measurement

Socio-demographic characteristics were collected from counselees after the initial consultation. Women were also asked whether they had lost family member(s) due to breast or ovarian cancer, if they had received psychological help after the receipt of the test result.

Clinical data were collected from medical records. Breast cancer risk estimates were computed at T1 and just before the test result disclosure using the 'Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA)' web application (BWA v3, University of Cambridge, Cambridge, UK) 39 (data only available for IC, Paris and CUH, Cologne).

Possible gene panel testing results included: 1) a pathogenic variant on BRCA1/2 or 2) other high/moderate-risk gene, or 3) a non-informative result (no pathogenic variant in index person), or 4) a VUS. Possible targeted gene testing included either a high/moderate-risk pathogenic variant or true negative result (no pathogenic variant in predictive tested healthy woman).

Outcomes consist in the genetic-specific psychosocial problems which were assessed at T1 and T2 using the 26-item 'Psychosocial Aspects of Hereditary Cancer' (PAHC) questionnaire 31 translated according to standard guidelines 41 and comprehensively assessed for psychometric performance (Brédart et al., The 'Psychosocial Aspects in Hereditary Cancer' questionnaire in women attending breast cancer genetic clinics: reliability, validity, responsiveness and interpretability across French-, German- and Spanish versions. Under review). A six-factor PAHC model yielded acceptable confirmatory factor analysis goodness-of-fit indexes ($\chi^2/df = 3.64$, RMSEA = 0.061 [90%CI: 0.057-

0.066], CFI = 0.91, TLI = 0.90), providing scales about concerns about hereditary predisposition (e.g., coping about the DNA test result) (HP), family and social issues (e.g., contacting family members about genetic testing) (FSI), emotions (e.g., insecure about the future) (E), familial cancer (e.g., worry that a family member would have cancer) (FC), personal cancer (e.g., worry about chance of getting cancer (again)) (PC), and children-related issues (e.g., guilt about passing the genetic alteration) (CRI). These PAHC scales demonstrated expected conceptual differences with distress and satisfaction with counselling. Different inter-individual levels of psychosocial difficulties were evidenced (p values < 0.05). We also assessed the PAHC ability to respond to change (i.e., intra-individual improvement or deterioration) in perceived difficulties, and computed a minimal clinically important difference threshold in PAHC scores comparing these scores with self-reported needs for additional counselling (i.e., resolution or development of further counselling needs before and after testing) which yielded a 10% change threshold on the PAHC score 1 to 100 score range. Internal consistencies for these scales administered at T1 and T2 were adequate with Cronbach's alphas of 0.84 and 0.84 for HP, 0.72 and 0.81 for FSI, 0.87 and 0.89 for E, 0.79 and 0.83 for FC, 0.71 and 0.65 for PC, and 0.73 and 0.74 for CRI.

Psychosocial covariates included generic distress (i.e., anxiety and depression) was measured at T2 by the Hospital Anxiety and Depression Scale (HADS), available in French 42, German 43 and Spanish 44 versions. Scores range from 0 to 42; a cut-off of 12 versus 13 has been proposed to identify possible cases of distress 42 45. Additionally, counselee's perceived lifetime risks of developing (new or recurrence) BC was measured at T2 in words and in figures. As responses to these items were highly correlated ($r=0.86$), a single variable was created. Taking the 'Don't know' response apart, other response categories of both items were coded from 0 ('Not concerned') to 6 ('Major risk' or 'over 80%') and an average score was derived. The later variable was then recoded as 0 ('Don't know'; 'Not concerned'), 1 ('Low risk' below 2.5), 2 ('Moderate risk' between score 2.5-3.5) and 3 ('High risk' above 3.5).

To address potential questionnaire non-responses, when necessary, a reminder call was made two weeks after the date of expected questionnaire receptions. Questionnaires not received within one month after the initial visit and within three months after the post-test genetic visit were considered missing. A sample size of 500 counselees was targeted in order to compare groups of at least 50 counselees by main genetic test results (i.e., positive, negative or VUS) and allow for multivariate analyses. Questionnaire completion online was possible through CleanWeb technology.

Statistical analyses

Statistical analyses were performed with R software 46. Sociodemographic and clinical characteristics were described using mean (standard deviation) or median (range) for continuous variables, and the number (percentage) for categorical variables. Respondents were defined as having provided one response at least to the socio-demographic and PAHC questionnaires. For each multi-item scale, missing data were replaced by the mean value of the scale when at least half of the items on that scale had been completed.

We used the F-test (ANOVA) for continuous data and the Chi-square test for categorical data to compare respondents and non-respondents at T1 (for age, parental and disease status), respondents by country settings and differences in PAHC mean scale scores by test result and country. Respondents and non-respondents at T2 were compared using logistic regression, accounting for country, age, education, marital and parental status, loss of a relative due to BC or OC, BC status, genetic test type, BC (new) risk perception, distress and genetic-specific problems at T1. Paired Student t-test was used to compare PAHC mean scale scores over assessment times and by countries, with Bonferroni correction.

Multiple regression analyses were performed on PAHC scale scores at T2 as the dependent variables and in order to estimate the effect of the test result (i.e., the change before and after testing may reflect the effect of genetic testing), we controlled for PAHC scores at T1. In addition, for each regression model, we also controlled for possible risk or protective factors of psychosocial problems 47 48, including country, socio-demographic (age, education level, marital and parental status) and clinical factors (BC diagnostic status, reported loss of family member(s) due to BC or OC), the type of genetic test (targeted or panel), BC risk perception and distress after the test result disclosure, the length of time between the pre- and post-test consultations and psychological help receipt after test disclosure. We also tested the interaction between PAHC scale scores at T1 and the test result on PAHC scale scores at T2.

Multiple regression analyses were performed 49 in which, in all models, covariates were introduced in a first block, the test result in a second block, and the interaction terms in a third block. As the effect of the type of genetic test was confounded with the comparison of true negative (only identified in counselees' undergoing targeted testing) and negative uninformative, these results were lumped together. Similarly, as the effect of a pathogenic variants on another high/moderate-risk gene was confounded with country (among 19 of these, 18 were identified in the German sample), all pathogenic gene variant results were grouped. The reference category was the negative results (true and uninformative) to which we compared either pathogenic variants or VUS results. There was no concern about multicollinearity given that all variables displayed a VIF (variance inflation factor) inferior to an acceptable value of 4.4 50.

Results

Description of the samples

Among 752 counselees consecutively approached, 213 and 172 (82.6% and 66.7%) in France, 300 and 220 (92.6% and 67.9%) in Germany and, 133 and 68 (78.2% and 40.0%) in Spain, respectively, completed the questionnaires after pre-test (T1) and post-test (T2).

Table 1 displays socio-demographic and clinical characteristics of the French, German and Spanish respondents. Less than 12 missing data were observed in women self-reported information. Their mean ages (standard deviation) were of 48.0 (11.9), 47.4 (10.7) and 47.9 (12.0) years, and 171 (80.3%), 254 (84.7) and 85 (63.9) of them were affected with BC, respectively.

Based on the BOADICEA BC risk estimation model 39, the mean (standard deviation) percent of BC lifetime risk estimates by age 80 before testing was 19.6 (11.9) and 18.1 (9.2) in France and Germany, respectively (data not available in Spain).

Country samples differed significantly in terms of level of education ($p < 0.0001$) and BC diagnosis status ($p < 0.0001$). At T1, there was no significant difference between respondents and non-respondents on age, having children, BC diagnosis and, for the French and German samples, on BOADICEA estimates. At T2, respondents and non-respondents differed on BC diagnosis and country samples such that women affected with BC and from the German relative to the Spanish setting were more frequently respondents ($p < 0.05$).

Insert table 1 about here

Seventy-nine (17.2%), 19 (4.1%), 259 (56.3%), 44 (9.6%) and 59 (12.8%) women received a pathogenic BRCA1/2 or high/moderate-risk variant other than BRCA1/2, uninformative, true negative or VUS result. The median length of time between the initial and test disclosure consultations was shorter in Germany (56 days) compared to France (183 days) and Spain (98 days) (Supplementary online material S2).

After testing, 20 (11.6), 32, (15.3) and 7 (10.3) counselees had received psychological help respectively ($p < 0.05$ for comparison between countries), and among them 11 (61.1%), 19 (65.5%) and 3 (42.9%) had been referred by a genetics clinician, in the French, German and Spanish setting, respectively.

Change in genetic-specific psychosocial problems over assessment time

On the PAHC questionnaire, the level of missing data per item was below 5% in all three countries. At both assessment times, mean scores of psychosocial problems were lowest in the 'Familial/Social Issues' domain across countries, ranging from 11.9 in Spain to 16.6 in Germany. After testing, psychosocial problem mean scores were highest in the 'Familial Cancer' domain in France (65.8) and Spain (79.0), and in 'Personal Cancer' (55.0) in Germany (Table 2).

Insert table 2 about here

Over assessment times, an overall statistically significant decrease was observed in the following concerns: 'Hereditary Predisposition' ($p < 0.001$), 'Personal Cancer' ($p < 0.05$) and 'Children-Related Issues' ($p < 0.001$). This decrease was also statistically significant for 'Hereditary Predisposition' in France ($p < 0.01$) and Germany ($p < 0.001$), and for 'Children-Related Issues' only in Germany ($p < 0.001$). No statistically significant decrease appeared in psychosocial problems related to 'Familial and Social Issues', 'Emotion' and 'Familial cancer'.

Among scales displaying a statistical difference over time, this decrease was clinically significant (according to the validated 10% change threshold in PAHC scale scores) only in concerns about 'Hereditary Predisposition' (10.7) and 'Children-Related Issues' (11.8) in the German sample.

Mean change in genetic-specific psychosocial problems by genetic test results and country

Bivariate analyses were performed comparing test results on mean changes in levels of psychosocial problems before and after testing (Table 3). A statistically significant difference between test results appeared on change in hereditary predisposition and familial/social issues ($p < 0.01$).

Only women receiving a TN or a VUS presented a clinically significant decrease and only women receiving a VUS decreased clinically in familial/social difficulties; although increasing in women receiving a PV or TN result, these changes did not reach clinical significance.

A statistically significant difference between countries was also observed on familial/social issues' ($p < 0.05$). PAHC scores at T2 only by test result and country are provided in Supplementary online material S3 and details of table 3 in Supplementary online material S4.

Insert table 3 about here

Multiple regression analyses

In multiple regression analysis (Table 4), across models including covariates, the genetic test result and the interaction between the test result and PAHC scale scores at T1, the percentage of explained variance (adjusted R^2) in domains of psychosocial problems at T2 ranged from 28% (Hereditary Predisposition) to 60% (Emotion) (all $p < 0.001$).

Insert table 4 about here

Only adding the test result to covariates in these models improved the prediction of psychosocial problems in 'Hereditary Predisposition' ($p < 0.01$) and 'Familial and Social Issues' ($p < 0.05$). Compared to a negative test result (true negative and uninformative), receiving a VUS was associated to lower problems in 'Hereditary Predisposition' ($\beta = -0.11$, $p < 0.05$). Addition of the combined effect of the test result and PAHC scale scores at T1 tended to be significant for scores in 'Hereditary Predisposition' ($F(2,381) = 2.9$, $p < 0.06$) and was significant for 'Familial and Social Issues' ($F(2,365) = 3.7$, $p < 0.05$). The effect of scores at T1 on scores at T2 was weaker for a VUS than other genetic test results (figures showing the interactions in Supplementary online material S5).

Among covariates, compared to Germany, counselees in Spain presented higher levels of problems in 'Hereditary Predisposition' ($\beta = 0.14$, $p < 0.01$), 'Familial Cancer' ($\beta = 0.11$, $p < 0.05$) and 'Children-Related Issues' ($\beta = 0.21$, $p < 0.001$). Distress and PAHC scores at T1 significantly predicted all problems (β ranging from 0.13, $p < 0.01$, for distress and 'Children-Related Issues' to 0.61, $p < 0.001$, for T1 PAHC scores and 'Familial Cancer'). Being affected with BC was associated to higher problems in 'Personal Cancer' ($\beta = 0.18$, $p < 0.05$). Compared to women who reported not knowing their risk of BC, those who presented a low risk perception presented lower 'Familial Cancer' and 'Personal cancer' scores ($\beta = -0.10$, $p < 0.05$). The receipt of psychological help after testing was associated to higher problems in the 'Emotions' domain ($\beta = 0.09$, $p < 0.01$).

Other covariates did not significantly predict psychosocial problems.

Discussion

In this study, we assessed changes in a comprehensive range of specific psychosocial problems before and after genetic testing, in women undergoing gene panel or targeted testing for HBOC syndrome in three European country genetics clinics and compared these changes according to the test result received and the problem levels before testing. Information on the extent to which genetic testing presents gaps in responding to counselees' psychosocial needs 14 and focus for improved counselling could thus be provided.

Psychosocial problems only decreased in the domains of hereditary predisposition, personal cancer, and children-related issues but this decrease was clinically significant only in German participants and for hereditary predisposition and children-related domains. Problems in the remained high, especially in the domains of personal and familial cancer, and children-related issues (mean level above 33 corresponding to Eijzenga et al. 31 cut-off score converted on a 0-100 scale indicating need of clinical attention). These problems concern pain about the (possible) loss of family members, fear of developing (new or recurrence) cancer or increased cancer risk in children, which were also highly prevalent in women from HBOC syndrome in other country settings 32 51.

In multivariate analyses, the genetic test result was associated to psychosocial problems only in domains of hereditary predisposition and familial and social issues. This study findings and the high level of problems underlines the overall impact of undergoing HBOC genetic testing, whatever the actual test result communicated 52. Two months after the test result disclosure, women carrying a pathogenic variant or an uninformative test result revealed little change in problems related to 'Hereditary predisposition' and so remaining needs in aspects such as clinical decision-making.

We acknowledge the following limitations in this study. Samples comprised women opting for genetic testing and test result disclosure, and who were mainly affected with BC, reflecting current population of counselees in the participating centres (respondents did not differ on key available characteristics). Recruiting counselees from only one genetics clinic per country did not allow differentiating between the potential effect of the country and genetics clinic. We could not systematically record which clinician met which counselee and so the variability between clinicians was not controlled. The communication content was validated during multidisciplinary team meetings in the different settings; however, variability may have occurred in subtle aspects such as clinicians' communication style 53. As the rates of pathogenic variants on moderate-risk genes was small and almost only present in German participants, we could not adequately contrast this type of test result with others. Finally, as the outcome measure was specifically designed for individuals undergoing genetic counselling in order to highlight further counselling needs after testing, we could not compare levels of difficulties in our samples with an appropriate control group.

Unexpectedly 36, women receiving a VUS result decreased in problems related to hereditary predisposition, almost independently from their levels of problems before testing. The effect of the test result may partly reflect the information provided during counselling. Lower problems in women receiving a VUS result compared to non-carriers suggests a particular attention to the content of counselling in the case of this particular genetic test result. A VUS result raises uncertainty about clinical management 22. In these study settings, the message conveyed by the communication of a VUS seemed more reassuring than that of an uninformative negative test result. Recommendations for managing VUS have recently been issued, advising that counselees may be re-contacted if a VUS is reclassified into 'clinically actionable' or 'definitively non-pathogenic' 18. Adherence to these guidelines may avoid detrimental between-clinicians discordant messages 54. This information imparted to counselees may have led them to put their concerns and expectations on-hold while non-carriers, mostly individuals receiving an uninformative result in these samples, remained

uncertain about their cancer risk status (e.g., how to explain one's BC diagnostic) and its medical consequences.

Problems in familial and social issues were relatively low and significantly different across test results: in women carriers of a pathogenic variant and those receiving a true negative result, these problems increased (non-significantly), which may be explained by the need to inform relatives after learning one's test result. This may be challenging, especially to those tested positively 55 or, elicit feelings of guilt in non-carriers towards family members who might receive a pathogenic result 7, therefore causing need for additional counselling for familial or social support and communication 56 57.

Distress was strongly related to all domains of psychosocial problems two months after the receipt of the test result 32 48, highlighting the many facets underlying distress that may be targeted for counselling. The role of genetic clinicians, psychologists or psychosocial workers with regard to psychosocial problems specific to the genetic context is not clearly delineated 58. The effect of genetic testing on psychosocial problems related to hereditary predisposition concerns suggests that genetic clinicians played a main role in that domain. A recent study observed that genetic counsellors define their role regarding psychosocial problems as short-term, referring counsees to mental health services when they perceive limited social support or significant anxiety related to a high-risk status or recent cancer diagnosis 58. Psychological care after the test result receipt was associated to higher negative emotions, suggesting that more distressed counsees received psychological care or that this was ineffective in reducing negative emotions two months after the receipt of test result. Less than 15% of counsees received psychological care after testing and among these about 40% to 60% of them had been referred by genetics clinicians depending on the country setting. This study suggests the need to improve access and uptake of psychosocial counselling in women undergoing genetic testing for cancer susceptibility 8 59.

As expected due to possible dissimilarities in cultural values and expectations 60 and genetic counselling modalities 61, significant differences in some genetic-specific problems were observed between countries. Concerning genetic counselling, variations between study settings in terms of clinicians' background, risk communication precision (e.g., in figures in addition to words) and psychological care availability may partly explain these differences. Aspects of the genetic counselling consultation such as the content of risk communication and approach to facilitate coping and decision making in relation to resolution of psychosocial problems require further research 62.

Conclusions

In women tested for breast or ovarian cancer genetic risk in one of three European cancer genetics clinics, specific psychosocial problems were mostly unaffected by genetic testing. Apart from women who received a VUS, those with another test results presented unchanged needs in counselling in particular about hereditary predisposition and familial/social issues.

Funding and acknowledgment: This project has received funding from the European Union Horizon 2020 research

and innovation programme under grant agreement No 634935 (BRIDGES). In France, this work has been partly financed through the SiRIC label, which has designated the Institut Curie an integrated

cancer research site and a grant from Ile-de-France Cancer Pole N° 2015-1-EMERG-14-ICH-1. We are grateful to clinical geneticists and counsellors from the Curie Institute, the University Hospital of Cologne, and the Catalan Oncology Institute of Barcelona, for inviting counselees to participate in the study, and thank all participants who provided their time to complete the questionnaires.

Compliance with Ethical Standards

This study protocol was approved in France by the Comité consultatif sur le traitement de l'information en matière de recherche dans le domaine de la santé (CCTIRS: Consultative committee for information management in health research – N°16.314), in Germany by the Ethics Committee of the University Hospital of Cologne (N°16-098) and, in Spain by the Ethics Committee of the Instituto Catalán de Oncología of Barcelona (N° - PR111/16). All recruited women provided written informed consent.

Competing interests

Dr Peter Devilee reports grants from EU Horizon2020 program during the conduct of the study. Other authors declare no conflict of interest.

Role of authors and contributors:

AB, JLK, PD, DSL, RS and SD designed the project.

AB, JD, AC, ADP, JB, DSL, RS and SD collected data.

AB, JLK, JD, DSL, AA, RS and SD analysed, interpret data and draft the work.

All authors revised and provided final approval of the version to be published.

Data availability

The study database is hosted at Methodology and Quality of Life in Oncology unit (INSERM UMR 1098), University Hospital of Besançon. It may be available after main publication for BRIDGES research program performed (in 2022).

References

1. Fountzilias C, Kaklamani VG. Multi-gene Panel Testing in Breast Cancer Management. *Cancer Treat Res* 2018;173:121-40. doi: 10.1007/978-3-319-70197-4_8 [published Online First: 2018/01/20]
2. Domchek SM, Bradbury A, Garber JE, et al. Multiplex genetic testing for cancer susceptibility: out on the high wire without a net? *J Clin Oncol* 2013;31(10):1267-70. doi: JCO.2012.46.9403 [pii] 10.1200/JCO.2012.46.9403 [published Online First: 2013/03/06]
3. Couch FJ, Nathanson KL, Offit K. Two decades after BRCA: setting paradigms in personalized cancer care and prevention. *Science* 2014;343(6178):1466-70. doi: 10.1126/science.1251827
4. Taylor A, Brady AF, Frayling IM, et al. Consensus for genes to be included on cancer panel tests offered by UK genetics services: guidelines of the UK Cancer Genetics Group. *J Med Genet* 2018;55(6):372-77. doi: 10.1136/jmedgenet-2017-105188
5. Meiser B. Psychological impact of genetic testing for cancer susceptibility: an update of the literature. *Psychooncology* 2005;14(12):1060-74. doi: 10.1002/pon.933
6. Hirschberg AM, Chan-Smutko G, Pirl WF. Psychiatric implications of cancer genetic testing. *Cancer* 2015;121(3):341-60. doi: 10.1002/cncr.28879
7. Eijzenga W, Hahn DE, Aaronson NK, et al. Specific psychosocial issues of individuals undergoing genetic counseling for cancer - a literature review. *J Genet Couns* 2014;23(2):133-46. doi: 10.1007/s10897-013-9649-4 [published Online First: 2013/09/03]
8. Vos J, van Asperen CJ, Oosterwijk JC, et al. The counselees' self-reported request for psychological help in genetic counseling for hereditary breast/ovarian cancer: not only psychopathology matters. *Psychooncology* 2013;22(4):902-10. doi: 10.1002/pon.3081
9. Gadzicki D, Evans DG, Harris H, et al. Genetic testing for familial/hereditary breast cancer-comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany. *J Community Genet* 2011;2(2):53-69. doi: 10.1007/s12687-011-0042-4 [published Online First: 2011/11/24]
10. Kreienberg R, Albert, U.-S., Follmann, M., Kopp, I.B., Kühn, T., Wöckel, A. Interdisciplinary GoR level III Guidelines for the Diagnosis, Therapy and Follow-Up Care of Breast Cancer. *Geburtshilfe Frauenheilkd* 2013;73(6):556-83.
11. Llort G, Chirivella I, Morales R, et al. SEOM clinical guidelines in Hereditary Breast and ovarian cancer. *Clin Transl Oncol* 2015;17(12):956-61. doi: 10.1007/s12094-015-1435-3 [published Online First: 2015/12/17]
12. Moretta J, Berthet P, Bonadona V, et al. [The French Genetic and Cancer Consortium guidelines for multigene panel analysis in hereditary breast and ovarian cancer predisposition]. *Bull Cancer* 2018;105(10):907-17. doi: 10.1016/j.bulcan.2018.08.003
13. Resta RG. What have we been trying to do and have we been any good at it? A history of measuring the success of genetic counseling. *Eur J Med Genet* 2018 doi: 10.1016/j.ejmg.2018.11.003 [published Online First: 2018/11/11]
14. Cragun D, Zierhut H. Development of FOCUS-GC: Framework for Outcomes of Clinical Communication Services in Genetic Counseling. *J Genet Couns* 2018;27(1):33-58. doi: 10.1007/s10897-017-0145-0 [published Online First: 2017/10/13]
15. Slavin TP, Niell-Swiler M, Solomon I, et al. Clinical Application of Multigene Panels: Challenges of Next-Generation Counseling and Cancer Risk Management. *Front Oncol* 2015;5:208. doi: 10.3389/fonc.2015.00208 [published Online First: 2015/10/21]
16. Easton DF, Pharoah PD, Antoniou AC, et al. Gene-panel sequencing and the prediction of breast-cancer risk. *N Engl J Med* 2015;372(23):2243-57. doi: 10.1056/NEJMs1501341

17. Hiraki S, Rinella ES, Schnabel F, et al. Cancer risk assessment using genetic panel testing: considerations for clinical application. *J Genet Couns* 2014;23(4):604-17. doi: 10.1007/s10897-014-9695-6 [published Online First: 2014/03/07]
18. Eccles DM, Mitchell G, Monteiro AN, et al. BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance. *Ann Oncol* 2015;26(10):2057-65. doi: 10.1093/annonc/mdv278
19. Hamilton JG, Lobel M, Moyer A. Emotional distress following genetic testing for hereditary breast and ovarian cancer: a meta-analytic review. *Health Psychol* 2009;28(4):510-8. doi: 10.1037/a0014778
20. Stafford L, Flehr A, Judd F, et al. Experiences and interpretations of BRCA1/2 testing among women affected by breast or ovarian cancer who received a negative result. *J Community Genet* 2019 doi: 10.1007/s12687-019-00415-w [published Online First: 2019/03/29]
21. Vos J, Gomez-Garcia E, Oosterwijk JC, et al. Opening the psychological black box in genetic counseling. The psychological impact of DNA testing is predicted by the counselees' perception, the medical impact by the pathogenic or uninformative BRCA1/2-result. *Psychooncology* 2012 doi: 10.1002/pon.1864 [published Online First: 2010/11/13]
22. Makhnoon S, Garrett LT, Burke W, et al. Experiences of patients seeking to participate in variant of uncertain significance reclassification research. *J Community Genet* 2019;10(2):189-96. doi: 10.1007/s12687-018-0375-3 [published Online First: 2018/07/22]
23. Rini C, O'Neill SC, Valdimarsdottir H, et al. Cognitive and emotional factors predicting decisional conflict among high-risk breast cancer survivors who receive uninformative BRCA1/2 results. *Health Psychol* 2009;28(5):569-78. doi: 10.1037/a0015205
24. O'Neill SC, Rini C, Goldsmith RE, et al. Distress among women receiving uninformative BRCA1/2 results: 12-month outcomes. *Psychooncology* 2009;18(10):1088-96. doi: 10.1002/pon.1467 [published Online First: 2009/02/14]
25. Himes DO, Gibbons DK, Birmingham WC, et al. Female family members lack understanding of indeterminate negative BRCA1/2 test results shared by probands. *J Genet Couns* 2019 doi: 10.1002/jgc4.1147 [published Online First: 2019/06/15]
26. Murray ML, Cerrato F, Bennett RL, et al. Follow-up of carriers of BRCA1 and BRCA2 variants of unknown significance: variant reclassification and surgical decisions. *Genet Med* 2011;13(12):998-1005. doi: 10.1097/GIM.0b013e318226fc15 [published Online First: 2011/08/04]
27. Maheu C, Apostolidis T, Petri-Cal A, et al. French women's breast self-examination practices with time after undergoing BRCA1/2 genetic testing. *Fam Cancer* 2012;11(2):269-78. doi: 10.1007/s10689-012-9512-z [published Online First: 2012/02/22]
28. Esteban I, Vilaro M, Adrover E, et al. Psychological impact of multigene cancer panel testing in patients with a clinical suspicion of hereditary cancer across Spain. *Psychooncology* 2018;27(6):1530-37. doi: 10.1002/pon.4686 [published Online First: 2018/03/03]
29. Bradbury AR, Patrick-Miller LJ, Egleston BL, et al. Patient feedback and early outcome data with a novel tiered-binned model for multiplex breast cancer susceptibility testing. *Genet Med* 2016;18(1):25-33. doi: 10.1038/gim.2015.19 [published Online First: 2015/04/04]
30. Lumish HS, Steinfeld H, Koval C, et al. Impact of Panel Gene Testing for Hereditary Breast and Ovarian Cancer on Patients. *J Genet Couns* 2017;26(5):1116-29. doi: 10.1007/s10897-017-0090-y
31. Eijzenga W, Bleiker EM, Hahn DE, et al. Psychosocial Aspects of Hereditary Cancer (PAHC) questionnaire: development and testing of a screening questionnaire for use in clinical cancer genetics. *Psychooncology* 2014;23(8):862-9. doi: 10.1002/pon.3485 [published Online First: 2014/01/21]
32. Farrelly A, White V, Meiser B, et al. Unmet support needs and distress among women with a BRCA1/2 mutation. *Fam Cancer* 2013;12(3):509-18. doi: 10.1007/s10689-012-9596-5 [published Online First: 2012/12/25]

33. O'Neill SC, Evans C, Hamilton RJ, et al. Information and support needs of young women regarding breast cancer risk and genetic testing: adapting effective interventions for a novel population. *Fam Cancer* 2018;17(3):351-60. doi: 10.1007/s10689-017-0059-x
34. Beran TM, Stanton AL, Kwan L, et al. The trajectory of psychological impact in BRCA1/2 genetic testing: does time heal? *Ann Behav Med* 2008;36(2):107-16. doi: 10.1007/s12160-008-9060-9
35. Halbert CH, Stopfer JE, McDonald J, et al. Long-term reactions to genetic testing for BRCA1 and BRCA2 mutations: does time heal women's concerns? *J Clin Oncol* 2011;29(32):4302-6. doi: 10.1200/jco.2010.33.1561 [published Online First: 2011/10/13]
36. Bredart A, Kop JL, Depauw A, et al. Short-term psychological impact of the BRCA1/2 test result in women with breast cancer according to their perceived probability of genetic predisposition to cancer. *Br J Cancer* 2013;108(5):1012-20. doi: 10.1038/bjc.2012.599
37. Vandembroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *PLoS Med* 2007;4(10):e297. doi: 10.1371/journal.pmed.0040297 [published Online First: 2007/10/19]
38. Biomedicine Agency FHHA. Règles de bonnes pratiques en génétique constitutionnelle à des fins médicales (hors diagnostic prénatal). 2013 [Available from: https://www.has-sante.fr/portail/jcms/c_1360718/fr/regles-de-bonnes-pratiques-en-genetique-constitutionnelle-a-des-fins-medicales-hors-diagnostic-prenatal. accessed June 10, 2019 2019.
39. Lee AJ, Cunningham AP, Kuchenbaecker KB, et al. BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface. *Br J Cancer* 2014;110(2):535-45. doi: 10.1038/bjc.2013.730 [published Online First: 2013/12/19]
40. Hooker GW, Clemens KR, Quillin J, et al. Cancer Genetic Counseling and Testing in an Era of Rapid Change. *J Genet Couns* 2017;26(6):1244-53. doi: 10.1007/s10897-017-0099-2 [published Online First: 2017/04/24]
41. Kuliš D, Bottomley, A., Velikova, G., Greimel, E., Koller, M. on behalf of the EORTC Quality of Life Group. EORTC Quality of Life Group Translation procedure. 2017
42. Razavi D, Delvaux N, Farvacques C, et al. Screening for adjustment disorders and major depressive disorders in cancer in-patients. *Br J Psychiatry* 1990;156:79-83. [published Online First: 1990/01/01]
43. Herrmann-Lingen C BU, Snaith RP. HADS-D: Hospital Anxiety and Depression Scale - German; Manual. Bern: Hans Huber 2011.
44. Herrero MJ, Blanch J, Peri JM, et al. A validation study of the hospital anxiety and depression scale (HADS) in a Spanish population. *Gen Hosp Psychiatry* 2003;25(4):277-83. doi: [https://doi.org/10.1016/S0163-8343\(03\)00043-4](https://doi.org/10.1016/S0163-8343(03)00043-4)
45. Sollner W, DeVries A, Steixner E, et al. How successful are oncologists in identifying patient distress, perceived social support, and need for psychosocial counselling? *Br J Cancer* 2001;84(2):179-85. doi: 10.1054/bjoc.2000.1545 [published Online First: 2001/02/13]
46. Team. RC. R: A language and environment for statistical computing. R Foundation for Statistical Computing Vienna, Austria 2017 [Available from: <https://www.R-project.org/>.
47. Bredart A, Anota A, Dick J, et al. Patient-Centered Care in Breast Cancer Genetic Clinics. *Int J Environ Res Public Health* 2018;15(2) doi: 10.3390/ijerph15020319
48. Eijzenga W, Bleiker EM, Hahn DE, et al. Prevalence and detection of psychosocial problems in cancer genetic counseling. *Fam Cancer* 2015;14(4):629-36. doi: 10.1007/s10689-015-9809-9 [published Online First: 2015/05/15]
49. Tabachnick BG, Fidell, L.S. Using multivariate statistics, Fifth edition. 2007
50. O'Brien RM. A Caution Regarding Rules of Thumb for Variance Inflation Factors. *Quality & Quantity* 2007;41(5):673-90. doi: 10.1007/s11135-006-9018-6
51. Bjornslett M, Dahl AA, Sorebo O, et al. Psychological distress related to BRCA testing in ovarian cancer patients. *Fam Cancer* 2015;14(4):495-504. doi: 10.1007/s10689-015-9811-2
10.1007/s10689-015-9811-2 [pii] [published Online First: 2015/05/20]

52. Vos J, Oosterwijk JC, Gomez-Garcia E, et al. Exploring the short-term impact of DNA-testing in breast cancer patients: the counselees' perception matters, but the actual BRCA1/2 result does not. *Patient Educ Couns* 2012;86(2):239-51. doi: 10.1016/j.pec.2011.04.017
53. Douma KF, Smets EM, Allain DC. Non-genetic health professionals' attitude towards, knowledge of and skills in discussing and ordering genetic testing for hereditary cancer. *Fam Cancer* 2016;15(2):341-50. doi: 10.1007/s10689-015-9852-6
54. Makhnoon S, Shirts BH, Bowen DJ. Patients' perspectives of variants of uncertain significance and strategies for uncertainty management. *J Genet Couns* 2019;28(2):313-25. doi: 10.1002/jgc4.1075 [published Online First: 2019/01/13]
55. Eijzenga W, Bleiker EM, Ausems MG, et al. Routine assessment of psychosocial problems after cancer genetic counseling: results from a randomized controlled trial. *Clin Genet* 2015;87(5):419-27. doi: 10.1111/cge.12473 [published Online First: 2014/08/19]
56. Eisler I, Ellison M, Flinter F, et al. Developing an intervention to facilitate family communication about inherited genetic conditions, and training genetic counsellors in its delivery. *Eur J Hum Genet* 2016;24(6):794-802. doi: 10.1038/ejhg.2015.215 [published Online First: 2015/10/08]
57. Bowen DJ, Hyams T, Laurino M, et al. Development of FamilyTalk: an Intervention to Support Communication and Educate Families About Colorectal Cancer Risk. *J Cancer Educ* 2019 doi: 10.1007/s13187-019-1484-3 [published Online First: 2019/02/10]
58. Cunningham M, Morreale M, Trepanier A. Referrals to Mental Health Services: Exploring the Referral Process in Genetic Counseling. *J Genet Couns* 2018;27(1):289-300. doi: 10.1007/s10897-017-0147-y [published Online First: 2017/09/15]
59. Maheu C, Bouhnik AD, Nogues C, et al. Which factors predict proposal and uptake of psychological counselling after BRCA1/2 test result disclosure? *Psychooncology* 2014;23(4):420-7. doi: 10.1002/pon.3435
60. Fielding R, Lam WW, Shun SC, et al. Attributing variance in supportive care needs during cancer: culture-service, and individual differences, before clinical factors. *PLoS One* 2013;8(5):e65099. doi: 10.1371/journal.pone.0065099
61. Bonaiti-Pellie C, Andrieu N, Arveux P, et al. [Cancer genetics: estimation of the needs of the population in France for the next ten years]. *Bull Cancer* 2009;96(9):875-900. doi: 10.1684/bdc.2009.0943
62. Hooker GW, Babu D, Myers MF, et al. Standards for the Reporting of Genetic Counseling Interventions in Research and Other Studies (GCIRS): an NSGC Task Force Report. *J Genet Couns* 2017;26(3):355-60. doi: 10.1007/s10897-017-0076-9 [published Online First: 2017/02/27]

Figure 1. Design of the prospective comparative cohort study




Table 1. Socio-demographic and clinical characteristics of study participants by country setting

	French participants (N=213)	German participants (N=300)	Spanish participants (N=133)
Age (years)			
Mean (SD)	48.0 (11.9)	47.4 (10.7)	47.9 (12.0)
Median (Range)	48.0 (21-78)	48.2 (18-77)	48.0 (19-80)
Education level n (%) ****			
Compulsory education or below	6 (2.8)	37 (12.4)	45 (34.1)
Secondary or technical/vocational education	60 (28.4)	167 (56.0)	44 (33.3)
Higher education or above	145 (68.7)	94 (31.5)	43 (32.6)
Marital status n (%)			
Married/partnered	149 (70.3)	212 (71.4)	102 (77.3)
Others (widowed. separated/ divorced. single/never married)	63 (29.7)	85 (28.6)	30 (22.7)
Having children n (%) (Yes)	170 (79.8)	213 (71.0)	103 (77.4)
Personal breast cancer n (%) (Yes)			
Overall women ****	171 (80.3)	254 (84.7)	85 (63.9)
Women with gene panel test ⁵	168 (93.9)	242 (98.8)	82 (97.6)
Women with targeted test ⁵	3 (8.8)	12 (22.2)	3 (6.1)
Time since breast cancer diagnostic (months)*			
Mean (SD)	39.1 (62.3)	27.7 (65.4)	41.4 (70.3)
Median (Range)	13.3 (0.36-342.3)	4.0 (-0.99-490.5)	7.8 (0.69-390.8)
Having lost a family member due to breast/ovarian cancer n (%) (Yes)	86 (42.8)	128 (44.4)	60 (46.9)
BOADICEA breast cancer first or contralateral risk estimates			
Mean (SD)	19.6 (11.9)	18.1 (9.2)	/
Median (range)	17.7 (0.8 – 82.9)	16.6 (0.7 – 81.1)	/
Participants at T2	French participants (N=172)	German participants (N=220)	Spanish participants (N=68)
Psychological help since test result receipt n (%) (Yes)* ^E	20 (11.6)	32 (15.3)	7 (10.3)
Psychological help since test result receipt among counselees' referred by genetics clinician n (%) ⁵	11 (61.1)	19 (65.5)	3 (42.9)

Note: one BOADICEA BC risk estimates missing in French sample as not computed for bilateral breast cancer; other missing data (≤ 12) due to women self-report omissions. Significant difference between country setting: * $p < 0.05$, **** $p < 0.0001$. \$ Total n for gene panel and targeted testing are 179 and 34, 245 and 54, 84 and 49, in France, Germany and Spain, respectively. £ Missing data: n=11 and 1 in German and Spanish participants; § Missing data: n=2 and 3 for French and German participants.

Table 2: Bivariate analyses of genetic-specific psychosocial difficulties mean (standard deviation) score over assessment times, overall and for each country

Psychosocial difficulties (PAHC scales) <i>Mean (SD)</i>	French participants		German participants		Spanish participants	
	T1 N=213	T2 N=172	T1 N=300	T2 N=220	T1 N=133	T2 N=68
Hereditary predisposition (HP) ***	29.1 (20.2)	22.4 (20.4) **	33.7 (24.1)	23.0 (24.9) ***	45.4 (26.6)	35.7 (27.5)
Familial and social issues (FSI)	15.9 (17.3)	15.8 (16.7)	16.6 (16.7)	14.6 (20.4)	11.9 (16.0)	15.1 (20.3)
Emotions (E)	30.0 (23.1)	30.6 (24.1)	33.8 (24.3)	30.4 (22.8)	29.3 (23.3)	27.1 (24.0)
Familial cancer (FC)	67.7 (25.0)	65.8 (27.5)	51.9 (24.3)	50.3 (25.9)	80.0 (18.8)	79.0 (21.4)
Personal cancer (PC) *	57.7 (27.0)	54.6 (28.5)	58.5 (28.6)	55.0 (27.2)	53.6 (31.8)	48.8 (29.8)
Children (CRI) ***	47.6 (26.7)	41.7 (27.7)	43.2 (26.9)	31.4 (25.4) ***	60.3 (25.3)	54.8 (25.5)

Notes: T1=assessment after the initial genetic consultation; T2= assessment two-months after the receipt of genetic test result. PAHC score range: [0-100]. Statistically significant difference between assessment times (with Bonferroni correction): *p<0.05; **p<0.01; ***p<0.001 and in bold clinically significant differences (over 10% change threshold in PAHC scale scores), overall and for each country setting.

Table 3. Bivariate analyses of mean (standard deviation) differences between T2 and T1 in genetic-specific psychosocial difficulties between test results

	PAHC 1 Hereditary predisposition (HP)	PAHC 2 Familial & social issues (FSI)	PAHC 3 Emotions (E)	PAHC 4 Familial cancer (FC)	PAHC 5 Personal cancer (PC)	PAHC 6 Children- related issues (CRI)
Genetic test result						
<i>BRCA1/2</i> pathogenic variant (n = 79)	-3.5 (23.1)	4.9 (17.7)	-0.1 (18.1)	-0.1 (19.6)	0.9 (22.2)	-2.7 (19.0)
Other high/moderate-risk pathogenic variant (n = 19)	-2.5 (22.7)	6.0 (28.3)	-3.2 (20.2)	-6.1 (25.3)	-8.8 (20.3)	-3.7 (21.7)
Negative (uninformative) (n = 259)	-7.3 (23.2)	-0.2 (17.1)	-1.9 (20.8)	-2.5 (19.8)	-3.3 (25.0)	-7.2 (23.0)
Negative (true) (n= 44)	-12.9 (24.6)	4.3 (17.2)	-4.0 (15.4)	1.4 (20.5)	-11.6 (29.7)	-11.7 (24.3)
VUS (n = 59)	-18.3 (29.8)	-6.5 (20.7)	-0.7 (25.8)	-3.0 (21.9)	-5.5 (21.3)	-11.9 (23.6)
Country						
France (n=172)	-5.7 (19.7)	1.7 (17.8)	0.5 (18.8)	-3.2 (21.9)	-2.7 (27.3)	-4.8 (23.0)
Germany (n=220)	-10.3 (26.6)	-1.5 (18.9)	-2.8 (21.5)	-1.4 (19.7)	-4.4 (20.6)	-10.0 (22.6)
Spain (n=68)	-9.5 (28.0)	4.5 (18.4)	-3.4 (21.1)	-0.6 (18.9)	-5.2 (29.5)	-5.5 (21.0)

Notes: T1=assessment after initial genetic consultation; T2= assessment two-months after receipt of genetic test result. PAHC=Psychosocial Aspects of Hereditary Cancer, score range=0-100, a difference of ~10 of the scale range is clinically significant. VUS=Variant uncertain significance. Overall statistically significant difference between test results on respondents at T1 and at T2: HP and FSI=**p<0.01 and between countries: FSI=**p<0.05.

Table 4: Multivariable analyses: effect of the genetic test result on scores of genetic-specific psychosocial difficulties at T2 controlled for scores at T1

	PAHC 1 Hereditary predisposition β	PAHC 2 Familial & social issues β	PAHC 3 Emotions β	PAHC 4 Familial cancer β	PAHC 5 Personal cancer β	PAHC 6 Children-related issues β
Country						
Spain versus Germany	0.14**	0.08	0.01	0.11*	0.03	0.21***
France versus Germany	0.04	0.05	0.02	0.01	-0.00	0.15 (0.063)
Age (years)	-0.01	-0.02	0.01	0.03	-0.06	0.06
Education level						
Secondary education versus compulsory or below	-0.06	-0.08	-0.01	-0.01	-0.02	0.03
Superior education versus compulsory or below	-0.09	-0.07	0.07	-0.02	-0.00	-0.04
Marital status (Married/partnered versus others)	0.00	-0.06	0.04	0.01	-0.03	-0.03
Having children (yes)	-0.03	-0.02	0.02	0.01	-0.00	-0.07
Having lost a family member due to breast/ovarian cancer (yes)	0.03	0.02	0.01	0.05	-0.05	0.00
Personal breast cancer (yes)	-0.06	-0.10	-0.07	-0.06	0.18*	0.04
Type of genetic test (Gene panel versus targeted test)	0.06	0.11	0.06	-0.05	0.04	0.01
Breast cancer risk perception at T2						
Don't know versus						
Low	-0.01	-0.05	-0.07	-0.10*	-0.10*	-0.10 (0.092)
Moderate	0.00	-0.06	-0.02	0.00	-0.03	0.00
High	0.02	0.06	0.06	-0.01	0.05	0.01
Generic distress (HADS) at T2	0.28***	0.21***	0.54***	0.23***	0.29***	0.13**
Psychological help at T2	-0.05	0.03	0.09**	0.01	0.06	0.03
Length of time bet. initial & genetic test disclosure consultations	-0.02	-0.00	-0.05	0.07	-0.00	0.00

	PAHC 1 Hereditary predisposition β	PAHC 2 Familial & social issues β	PAHC 3 Emotions β	PAHC 4 Familial cancer β	PAHC 5 Personal cancer β	PAHC 6 Children-related issues β
PAHC score at T1	0.39***	0.45***	0.30***	0.61***	0.41***	0.57***
Block 1 (control variables): F(df); R ² ; Adjusted R ²	9.2 (17,385); .29; .26	9.5 (17,369); .30; .27	36.1 (17,379); .62; .60	32.0 (17,386); .59; .57	26.1 (17,383); .54; .52	15.1 (17,282); .48; .44
Genetic test result						
High/moderate-risk pathogenic variant	0.07	0.06	-0.01	-0.03	-0.01	0.06
VUS	-0.11*	-0.08	0.02	-0.03	-0.04	-0.04
Block 2 (+ genetic test result): F(df); R ² ; Adjusted R ²	9.1 (19,383); .31; .28	9.0 (19,367); .32; .28	32.2 (19,377); .62; .60	28.7 (19,384); .59; .57	23.3 (19,381); .54; .51	13.7 (19,280); .48; .46
Difference between block 1 and block 2 : F (df) ; p	5.7 (2,383); 0.004	3.7 (2,367); 0.026	0.30 (2,377); 0.74	0.64 (2,384); 0.53	0.37 (2,381); 0.69	1.20 (2,280); 0.29
Interaction						
High/moderate-risk pathogenic variant x PAHC score at T1	0.02	0.01	-0.02	-0.07 (0.082)	0.00	-0.05
VUS x PAHC score at T1	-0.11*	-0.13*	-0.06 (0.076)	0.01	0.05	-0.02
Block 3 (+ genetic test result and PAHC scale interaction): F(df); R ² ; Adjusted R ²	8.6 (21,381); .32; .28	8.6 (21,365); .33; .29	29.4 (21,378); 62; .60	26.2 (21,382); .59; .57	21.1 (21,379); .54; .51	12.4 (21,278); .48; .44
Difference between block 2 and block 3 : F (df) ; p	2.9 (2,381); 0.055	3.7 (2,365); 0.027	1.6 (2,375); 0.20	1.71 (2,382); 0.18	0.66 (2,379); 0.52	0.46 (2,278); 0.63

Note: T1=assessment after the initial genetic consultation; T2= assessment two-months after the receipt of genetic test result. PAHC=Psychosocial Aspects of Hereditary Cancer; HADS=Hospital Anxiety and Depression Scale; VUS=Variant uncertain significance; *p<0.05, **p<0.01, ***p<0.001.

Supplementary material S1. Description of the genetic counselling intervention in the French, German, and Spanish clinics

Breast cancer (BC) gene counselling was based on specific guidelines in each country (Groupe Génétique et Cancer (GGC) in France [Biomedicine Agency-HAS, 2013; HAS, 2014; Moretta, 2018]; German Consortium for Hereditary Breast and Ovarian Cancer-German Gynaecological Oncology Group in Germany (GC-HBOC-AGO) [Kreienberg, 2013; AGO, 2017]; “Oncoguia” guidelines in Spain [Llort, 2015]. Genetic counselling was considered important, before and after testing [Gadzicki, 2011; Kreienberg, 2013; French Biomedicine Agency, 2013], and, in Germany, to be performed according to principles of patient centred communication [Kreienberg, 2013]. The goal was to allow informed counselees to accept or decline genetic testing. No psychotherapeutic model guided counselling.

Across guidelines, criteria for genetic testing for breast or ovarian cancer susceptibility varied slightly in terms of age thresholds (e.g., age 45 or 50 of BC onset) and number of family members affected with breast and/or ovarian cancer (two or three). The criteria of triple-negative or bilateral BC before age 51 and BC before age 36 were similar across guidelines. Gene panel testing was mainly performed to women affected with BC (index cases). A 12-gene, 34-gene, and 9-gene panel was tested in France (Paris), Germany (Cologne) and Spain (Barcelona), respectively. Targeted testing was proposed to relatives of pathogenic variant carriers.

Among gene panels, some genes were only tested for research purposes and a subset of results are disclosed to clinicians: in France, the genetic test result was communicated to counselees for *BRCA1*, *BRCA2*, *PALB2*, *RAD51C*, *RAD51D*, *MLH1*, *MLH2*, *MSH2*, *MSH6*, *PMS2* (among the 12-gene panel); in Germany, this was also the case for *ATM*, *CHEK2* and *BRIP1* and, in Spain for *ATM* and *CHEK2*; other high-penetrance susceptibility such as *TP53*, *CDH1*, *PTEN* genes were also tested and the test result communicated in the three centres.

In the different settings, genetic counselling was provided in face-to-face consultations with the counslee accompanied if desired by one or more family member(s). In the French setting, pre-test consultation was provided by one of five genetic counsellors with a biology background and the result disclosure by one of five medical geneticists. In the German setting, pre-test and post-test consultations were provided by one of ten physicians, including a medical geneticist and nine gynaecologists and in the Spanish setting, by one of four genetic counsellors with a background in biology for one them or nursing for the three others.

Supplementary material S2: Genetic testing information by country setting

	French participants (N=172)	German participants (N=220)	Spanish participants (N=68)
Type of genetic test n (%) ****			
Gene panel test	145 (84.3)	184 (83.6)	39 (57.4)
Targeted test	27 (15.7)	36 (16.4)	29 (42.6)
Genetic test result n (%) ****			
<i>BRCA1/2</i> pathogenic variant	27 (15.7)	36 (16.4)	16 (23.5)
Other high/moderate-risk pathogenic variant	1 (0.6)	18 (8.2)	0 (0.0)
Uninformative negative	117 (68.0)	118 (53.6)	24 (35.3)
True negative	14 (8.1)	16 (7.3)	14 (20.6)
Variant uncertain significance (VUS)	13 (7.6)	32 (14.5)	14 (20.6)
Length of time between initial and genetic test result disclosure consultations (days)			
Mean (SD) ****	163.6 (55.1)	61.1 (26.5)	100.5 (56.9)
Median (Range)	183 (42-324)	56 (22-184)	98 (21-260)
Psychological help since test result receipt n (%) (Yes)	20 (12.8)	32 (14.6)	7 (10.3)
Psychological help since test result receipt among counselees' referred by genetics clinician n (%)	10 (50.0)	19 (59.3)	3 (42.8)

Significant difference between country: ****p<0.0001; if positive test results are grouped (*BRCA1/2* and other gene positive), difference between countries is significant at p<0.01.

Supplementary material S3. Genetic-specific psychosocial difficulties and other psychological variables by country setting and genetic test result

	French participants				German participants				Spanish participants			
	Pathogenic variant	Uninformative	True Negative	VUS	Pathogenic variant	Uninformative	True Negative	VUS	Pathogenic variant	Uninformative	True Negative	VUS
	N=28	N=117	N = 14	N=13	N=54	N=118	N = 16	N=32	N=16	N=24	N = 14	N=14
	<i>BRCA1/2</i>				<i>BRCA1/2</i>				All			
	N=27				N=36				<i>BRCA1/2</i>			
Hereditary predisposition (HP) §,***	26.4 (18.7) 27.4 (18.3)	22.5 (20.7)	17.9 (20.0)	17.3 (22.6)	28.7 (24.5) 28.6 (24.7)	23.0 (25.4)	17.6 (20.1)	16.3 (24.7)	43.2 (26.2)	36.3 (30.3)	34.8 (31.7)	27.6 (18.1)
Familial and social issues (FSI)	16.4 (17.4) 16.4 (17.4)	16.2 (16.8)	11.1 (12.5)	15.6 (19.1)	22.8 (25.9) 21.7 (24.6)	12.3 (18.1)	10.0 (13.3)	11.2 (17.0)	11.6 (16.2)	18.1 (23.0)	19.5 (24.2)	9.0 (14.0)
Emotions (E)	37.1 (25.3) 38.2 (25.0)	29.4 (23.6)	25.8 (19.5)	31.7 (29.7)	31.1 (23.2) 32.4 (25.1)	31.5 (21.2)	21.3 (26.6)	29.4 (25.5)	28.0 (20.8)	30.1 (28.6)	21.0 (18.5)	27.1 (25.3)
Familial cancer (FC) ****	67.3 (28.1) 67.6 (28.6)	65.5 (27.4)	75.2 (21.9)	54.9 (31.3)	56.7 (26.7) 59.6 (27.8)	49.6 (24.6)	49.0 (27.0)	42.8 (27.3)	77.8 (21.7)	76.0 (20.6)	83.3 (23.6)	81.0 (21.8)
Personal cancer (PC) §§§§	51.8 (28.1) 51.2 (28.5)	58.0 (27.3)	32.1 (32.3)	55.1 (26.7)	52.5 (28.1) 52.8 (26.6)	60.2 (24.6)	27.8 (20.6)	53.1 (30.1)	45.6 (29.9)	54.2 (27.0)	31.0 (29.9)	60.7 (26.6)
Children-related issues (CRI) ****	42.7 (27.4) 42.7 (27.4)	41.7 (27.4)	34.0 (31.5)	45.5 (30.8)	40.9 (24.4) 40.5 (22.4)	30.3 (25.4)	17.2 (14.4)	24.6 (27.1)	54.5 (21.9)	54.0 (29.0)	59.3 (27.8)	51.9 (21.9)

Supplementary material S4. Note on table 3.

In table 3, in other high/moderate-risk pathogenic variants changes in scores appear to be greater than other results particularly in terms of familial cancer and personal cancer difficulties however the difference in changes across test results is not statistically significant, and changes for the other gene pathogenic variant do not reach clinical significance. In multivariate analyses, there was higher psychosocial difficulties related to hereditary predisposition, familial cancer and children-related issues after testing in the Spanish compared to the German sample and no difference between the French and German sample and so the higher proportion of pathogenic variants on moderate-penetrance genes (N=18 in Germany) may not explain that difference. Note that as expected, a clinically significant decrease in difficulties related to personal cancer (-11.6) and in children-related issues (-11.7) was revealed in women receiving a true negative result; however, the comparison between test results was not statistically significant.

Supplementary material S5. Figure a and figure b

Note: Figure a and figure b show the relationship between scores on the PAHC Hereditary predisposition and Familial/social issues at T1 on those at T2, showing that the relationship is different according to the test result. Controlled for other variables, standardized coefficients of the line slopes in figure a and b respectively are 0.41, 0.44 and 0.13 and 0.57, 0.59 and 0.19 for a pathogenic variant, negative result and VUS, respectively.

